Zion Market Research

Cystic Fibrosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2024

Cystic Fibrosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2024


Sarasota, FL -- (SBWIRE) -- 05/17/2018 -- Cystic Fibrosis Therapeutics Market: Overview

Cystic fibrosis is an autosomal recessive and monogenetic disorder as a result of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR is a protein (transmembrane) that transports ions across the surface of epithelial cells. CFTR dysfunction affects a number of organs but lung disease is responsible for the majority of mortality in patients with cystic fibrosis.

CF is an autosomal recessive disease as a result of mutations in a gene located on chromosome 7. The CFTR is a single polypeptide protein containing 1480 amino acids that is observed to function both as a cyclic AMP-regulated, Cl- channel and as a regulator of other ion channels. The fully organized form of CFTR is found in the plasma membrane in normal epithelia. In a normal functioning cell, CFTR is synthesized in the rough endoplasmic reticulum (RER) followed by glycosylation in the Golgi apparatus and performing the function of a Cl- channel and regulator of other ion channels when located in the plasma membrane. However, there can be two possible mutations in the CFTR gene, viz., (1) If a mutation disturbs protein folding, CFTR is degraded intracellularly thus, no protein is transported to the plasma membrane. (2) With other mutations, the abnormal protein is processed, reaches to the plasma membrane but functions abnormally at that site.

Request For Free Sample Report: https://bit.ly/2rSFw0i

Cystic Fibrosis Therapeutics Market: Market Dynamics

The rising prevalence of Cystic Fibrosis (CF) globally, improved diagnostic technologies, growing investment in and awareness about genetic diseases, favorable initiatives undertaken by nonprofit organizations, development of the Healthcare industry and research and development activities undertaken by key players are expected to boost the market over the forecast period.

The market restraints include Cystic Fibrosis Related Complications, Increased Risk of Bacterial Infections in Cystic Fibrosis Patients, high cost involved in treatment and increase in complexity of disease. Observed new opportunities in Cystic Fibrosis Therapeutic market include, patent expiry of many innovator drug companies for Cystic Fibrosis leading to the introduction of generic drugs, Gene Therapy breakthrough for Cystic Fibrosis, better understanding of the genetic structure which would help in innovating new drugs/therapies.

Download Free Research Report Brochure: https://bit.ly/2GqHeuT

Segmentation based on Cystic Fibrosis therapeutic drug class:

Based on the therapeutic drug class the segmentation is, Mucolytics, CFTR modulators, Pancreatic enzyme supplements and Bronchodilators.

Segmentation based on Cystic Fibrosis therapeutic route of administration:

Based on the route of drug administration, Oral drugs and Inhaled drugs.

Segmentation based on regions:

North America lead the market for F.Y. 2016; as CF is most prevalent in North America due to the fact that most of the people affected with CF are of Caucasian descent, initiatives taken by Cystic Fibrosis Canada and CF Foundation are one of the key reasons that can be accounted for its largest share. Europe has the second-largest revenue share in global cystic fibrosis therapeutics, followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. It is a rapidly growing segment in Asia-Pacific due to rising awareness about CF disorders & various treatment options. In addition, economic development in this region and improving healthcare facilities drive the market in this region.

Inquiry Before Buying Report: https://bit.ly/2L94QaX

Cystic Fibrosis Therapeutics Market: Competitors

Key manufacturers of Cystic Fibrosis Therapeutics include, Hoffmann-La Roche Ltd, Gilead Sciences Inc, Merck & Co Inc, AbbVie Inc, Allergan plc, Alcresta Therapeutics Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, AstraZeneca Plc. among others

Cystic Fibrosis Therapeutics Market: Regional Segment Analysis

North America
The U.S.
The UK
The Asia Pacific
Latin America
The Middle East and Africa

Browse the full report at: https://bit.ly/2Gn8kDf

About Zion Market Research
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.